Efficacy and Safety of Bortezomib，Lenalidomide Combined with Dexamethasone in the Treatment of Multiple Myeloma

Jianmei LI; Yanling JIN

doi:10.12259/j.issn.2095-610X.S20230610

Volume 44 Issue 6

Jun. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2023 > 44(6): 120-125

Jianmei LI, Yanling JIN. Efficacy and Safety of Bortezomib，Lenalidomide Combined with Dexamethasone in the Treatment of Multiple Myeloma[J]. Journal of Kunming Medical University, 2023, 44(6): 120-125. doi: 10.12259/j.issn.2095-610X.S20230610

Citation:

Jianmei LI, Yanling JIN. Efficacy and Safety of Bortezomib，Lenalidomide Combined with Dexamethasone in the Treatment of Multiple Myeloma[J]. Journal of Kunming Medical University, 2023, 44(6): 120-125. doi: 10.12259/j.issn.2095-610X.S20230610

Citation:

PDF( 634 KB)

Efficacy and Safety of Bortezomib，Lenalidomide Combined with Dexamethasone in the Treatment of Multiple Myeloma

doi: 10.12259/j.issn.2095-610X.S20230610

Jianmei LI,
Yanling JIN^,

Hematology Department，First People’s Hospital of Qujing City，Qujing Yunnan 655099，China

Received Date: 2023-03-16
Available Online: 2023-06-16
Publish Date: 2023-06-25

Abstract

Abstract

Objective To investigate the therapeutic efficacy and safety of bortezomib and lenalidomide combined with dexamethasone in patients with Multiple Myeloma （MM）. Methods A total of 94 patients with multiple myeloma in the Hematology Department of the First People’s Hospital of Qujing City from September 2021 to September 2022 were selected and divided into 2 groups by random number table method. The control group （n = 47 cases） was treated with bortezomib combined with dexamethasone, and the observation group （n = 47 cases） bortezomib, dexamethasone and lenalidomide. One course of treatment lasted for 3 weeks, and a total of 6 courses of treatment were conducted. The effective rate, blood biochemical indexes, immune level, disease load and adverse reactions of the two groups were compared. Results After treatment, the effective rate of observation group was higher than that of control group, the difference was statistically significant （P < 0.05）. After treatment, bone marrow plasma cells and blood M protein levels in the observation group were lower than those in the control group, and the difference was statistically significant （P < 0.05）. BAP, OPG and LDH in observation group were higher than those in control group, and the differences were statistically significant （P < 0.05）. CD³⁺, CD⁴⁺, CD⁴⁺/CD⁸⁺ in observation group were higher than those in control group, and CD⁸⁺ were lower than those in control group, the difference was statistically significant （P < 0.05）. The percentage of bone marrow plasma cells, the level of M protein and the level of free light chain were decreased in 2 groups. There was no significant difference in the incidence of bone marrow suppression, fingertip numbness, alopecia, kidney damage and gastrointestinal reaction between 2 groups （P > 0.05）. Conclusion Bortezomib, lenalidomide combined with dexamethasone for 6 consecutive courses of treatment can improve the treatment efficiency of multiple myeloma patients, improve their blood biochemical indexes, increase the levels of CD³⁺, CD⁴⁺, CD⁴⁺/CD⁸⁺, and significantly improve the drug safety factor, worthy of promotion and application.
- Bortezomib,
- Lenalidomide,
- Dexamethasone,
- Multiple myeloma,
- Efficacy rate,
- Immune level,
- Safety

FullText(HTML)

References(17)

References

[1]	罗曼,胡莉文,古学奎,等. 来那度胺长期维持治疗对多发性骨髓瘤患者的临床疗效和预后评估[J]. 中国实验血液学杂志,2021,29(2):540-546.
[2]	王权钢,白波,马梁明,等. 初诊多发性骨髓瘤患者CD56表达与以硼替佐米联合来那度胺为基础方案诱导治疗疗效的临床研究[J]. 临床血液学杂志,2022,35(11):821-825.
[3]	曹红花,吴娜,贺鸣等. 皮下注射硼替佐米为主化疗方案治疗多发性骨髓瘤[J]. 昆明医科大学学报,2019,40(5):49-52.
[4]	王文秀,毕静怡,温磊,等. 来那度胺联合硼替佐米及地塞米松治疗初治多发性骨髓瘤单中心100例连续病例的回顾性分析[J]. 中华内科杂志,2022,61(5):531-536. doi: 10.3760/cma.j.cn112138-20211105-00776
[5]	许晗,王梦莹,姜骁娜,等. 硼替佐米联合来那度胺和地塞米松治疗新诊断多发性骨髓瘤疗效及安全性分析[J]. 临床血液学杂志,2022,35(1):46-51,57. doi: 10.13201/j.issn.1004-2806.2022.01.009
[6]	Facon T,Venner C,Bahlis N,et al. Oral ixazomib,lenalidomide,and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.[J]. Blood,2021,137(26):3616-3628. doi: 10.1182/blood.2020008787
[7]	郭秋霞,王吉刚,刘彦琴,等. 来那度胺对多发性骨髓瘤患者自体移植造血干细胞采集影响[J]. 临床军医杂志,2021,49(1):37-39,43.
[8]	Witenko C J,Littlefield A J,Abedian S,et al. Reply:the safety of continuous infusion propofol in mechanically ventilated adults with coronavirus disease 2019[J]. Annals of Pharmacotherapy,2022,56(5):628-629. doi: 10.1177/10600280211043188
[9]	蓝梅,罗静,李学军,等. 自体外周血干细胞输注过敏性休克经综合治疗再次成功回输1例报告[J]. 国际免疫学杂志,2021,44(4):484-486.
[10]	董珂,胡桂芳,王云,等. 硼替佐米联合环磷酰胺及地塞米松对老年多发性骨髓瘤患者免疫功能及炎性因子的影响[J]. 山西医药杂志,2022,51(5):524-526.
[11]	Kartik S,Rituparna D,Lin Z,et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets[J]. Blood,2021,125(26):4042-4051.
[12]	赵薇薇,陈丽艳,王连杰,等. 改良VTD-PACE方案治疗多发性骨髓瘤髓外病变及浆细胞白血病的疗效分析[J]. 哈尔滨医科大学学报,2021,55(1):36-40.
[13]	王瓒,李斑斑,李纯璞,等. 自体造血干细胞移植在多发性骨髓瘤治疗中的应用进展[J]. 山东医药,2021,61(35):101-104. doi: 10.3969/j.issn.1002-266X.2021.35.028
[14]	Ainley L,Camilleri M,Chavda S J,et al. Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression[J]. British Journal of Haematology,2022,196(6):e63-e66.
[15]	王向东,杨波,李素霞,等. 来那度胺方案治疗初治多发性骨髓瘤患者血栓事件发生率分析[J]. 解放军医学院学报,2021,42(3):273-276,296. doi: 10.3969/j.issn.2095-5227.2021.03.007
[16]	Davidoff A J,Long J B,Bewersdorf J P,et al. Multiple myeloma(MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status[J]. Journal of Clinical Oncology,2020,38(15_suppl):e19057-e19057. doi: 10.1200/JCO.2020.38.15_suppl.e19057
[17]	杨扬,夏忠军,张文皓,等. 伊沙佐米、来那度胺、地塞米松治疗复发/难治多发性骨髓瘤的疗效与安全性分析: 一项国内多中心真实世界研究[J]. 中华血液学杂志,2021,42(8):628-634. doi: 10.3760/cma.j.issn.0253-2727.2021.08.003

Relative Articles(20)

Relative Articles

[1]	Fen TENG, Bo TIAN, Chongxi LI, Yongmei JIN, Haiyun CHEN, Jun LIU. Real-World Clinical Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide （BIC/FTC/TAF） Single-Tablet Regimen. Journal of Kunming Medical University, 2024, 45(4): 74-80. doi: 10.12259/j.issn.2095-610X.S20240411
[2]	Yibiao GUAN, Sheng HUANG, Libo LI. Effect of Hybrid Blood Purification on Dialysis Adequacy，Immunity，and Inflammation in ESRD Patients with Inadequate Peritoneal Dialysis. Journal of Kunming Medical University, 2024, 45(8): 125-132. doi: 10.12259/j.issn.2095-610X.S20240818
[3]	Liyuan YUN, Junfeng WANG, Ning GUO, Ruimei DING, Haipeng LI, Xueping ZHANG. Analysis of the Efficacy and Safety of GM1 Injection Combined with Batroxobin in the Treatment of Sudden Deafness Patients. Journal of Kunming Medical University, 2024, 45(6): 140-144. doi: 10.12259/j.issn.2095-610X.S20240619
[4]	Keyan WANG, Bingting LIN, Xiaolin WENG, Bin HUANG, Lie WANG. Effectiveness and Safety Analysis of Cyclopol Combined with Remifentanil in Anesthesia for Endoscopic Gastric Cancer Radical Surgery. Journal of Kunming Medical University, 2024, 45(6): 154-160. doi: 10.12259/j.issn.2095-610X.S20240621
[5]	, . . Journal of Kunming Medical University, 2024, 45(1B): 9-10.
[6]	Yanling JIN, Jianmei LI. Efficacy and Safety of rhTPO Combined with High-dose Short-cycle Dexamethasone Regimen in Treatment of ANa-positive Adult Immune Thrombocytopenia. Journal of Kunming Medical University, 2022, 43(11): 146-150. doi: 10.12259/j.issn.2095-610X.S20221119
[7]	Zhi-rong ZHAO, Hai-wen LI, Ni-hong LU, Ling SHEN, Xiao-fei LI, Yong-rui YANG. A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B. Journal of Kunming Medical University, 2021, 42(1): 89-93. doi: 10.12259/j.issn.2095-610X.S20210141
[8]	Zhao-sen FENG, Yu FANG, Ding-qin OU, Yi-han YANG, Zhi-yao WANG, Jie HUANG. Clinical Effect of Dexmedetomidine and Dexamethasone as Adjuvants for Brachial Plexus Block. Journal of Kunming Medical University, 2021, 42(10): 68-75. doi: 10.12259/j.issn.2095-610X.S20211005
[9]	Cao Hong Hua , Wu Na , He Ming , Zhang Rui , Zhou Ye Ying , Lai Xuan , Shen Zheng Lei . . Journal of Kunming Medical University, 2019, 40(05): 49-52.
[10]	Wang Xue Jiao , Zhang Zhe , Yu Jing Xing , Li Yuan Yuan , Zhao Mei Shu , Yin Lie Fen . Mutiple Myeloma with Double Clones of IgD-λ+λ:Two Cases Report. Journal of Kunming Medical University, 2017, 38(09): 124-128.
[11]	Luo Yong Li . Clinical Assessment on the Safety of Cardiac Rehabilitation for the Elderly Patients with Chronic Heart Failure. Journal of Kunming Medical University,
[12]	Feng Zi Hao . Clinical Efficacy of Laparoscopic Operation Combined with Dexamethasone Cavity Flushing in Endometriosis. Journal of Kunming Medical University,
[13]	Zeng Hai Ping . . Journal of Kunming Medical University,
[14]	Ke Zi Li . . Journal of Kunming Medical University,
[15]	Xue Qiang . . Journal of Kunming Medical University,
[16]	Xie Zuo Zhou . . Journal of Kunming Medical University,
[17]	Wan Yun Yan . . Journal of Kunming Medical University,
[18]	He Zhen Xin . . Journal of Kunming Medical University,
[19]	Yan Jin . . Journal of Kunming Medical University,
[20]	Jiang Zhi Min . . Journal of Kunming Medical University,